However, based on our research, we make our point that TPD52 may restrain HCC tumorigenesis and development via up-regulating the expression of p21 and p53, and down-regulating the expression of tumor promoter including MDM2, P-GSK-3β and BCL2 in the context of PI3K/Akt signaling. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.